Complete Genomics (GNOM) Discloses $3.30/Sh Unsolicited Bid, Says Doesn't Not Constitute a Superior Proposal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Illumina (ILMN) Affirms Being 'Party H' in Complete Genomics' (GNOM) Filing
November 16, 2012 4:22 PM ESTOn November 16, 2012, Illumina, Inc. (Nasdaq: ILMN) confirmed that it is Party H as named in the Schedule 14D-9 (and related amendments) filed by Complete Genomics, Inc. (Nasdaq: GNOM) in connection with the tender offer by Beta Acquisition Corporation, a Delaware... More
BGI-Shenzhen to Acquire Complete Genomics (GNOM) for $3.15/Share Cash
September 17, 2012 6:32 AM EDTComplete Genomics, Inc. (Nasdaq: GNOM) and BGI-Shenzhen announced that they have entered into a definitive merger agreement. Through this agreement, a wholly-owned U.S. subsidiary of BGI will launch a tender offer to purchase all outstanding shares of common stock of Complete for $3.15 per share in cash, without interest. This price represents approximately a 54% premium to the $2.04 closing price per share of Complete common stock on June 4, 2012, the last trading day prior to Complete's announcement that it was undertaking an evaluation of strategic alternatives to secure the financial resources needed for continued commercialization of its technology.
Complete's board of directors has unanimously recommended that stockholders accept the offer and tender their shares. Based on the number of fully diluted outstanding shares of Complete, the aggregate value of the transaction is... More
